there is a good reference point at $2.91/share since $40 million is now invested at that price. That should provide a bottom. Because they are going it alone, any ramp in price is on hold for 12-18 months. Another catalyst is the FDA official minutes due soon. The meeting was positive but I don't expect any exciting news in the minutes.
Citi: Mgmt did note that it expects sales & marketing to be roughly $18-20M per year once fully ramped. By our initial estimates, we believe year 1 Iluvien EU revs could be about $10M and year 2 about $50-75M. Citi is neutral.
I was looking for them to get bought by a big pharma. Now I will start to reduce my shares on any rise and move on. Still have 33K shares.